• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

低密度脂蛋白受体相关蛋白6（LRP6）是一种与肾透明细胞癌预后及免疫浸润相关的潜在生物标志物。

LRP6 is a potential biomarker of kidney clear cell carcinoma related to prognosis and immune infiltration.

作者信息

Lu Liqun, Lei Yan, Li Yanling, Wang Lujuan

机构信息

Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.

Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China.

出版信息

Aging (Albany NY). 2024 Jan 15;16(2):1484-1495. doi: 10.18632/aging.205440.

DOI:10.18632/aging.205440
PMID:38226972
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10866424/
Abstract

Renal cell carcinoma is the most common and most lethal genitourinary tumor. The causes of renal clear cell carcinoma are complex and the heterogeneity of the tumor tissue is high, so patient outcomes are not very satisfactory. Exploring biomarkers in the progression of renal clear cell carcinoma is crucial to improve the diagnosis and guide the treatment of renal clear cell carcinoma. LRP6 is a co-receptor of the Wnt/β-catenin signaling pathway, which is involved in cell growth, inflammation and cell transformation through activation of the Wnt/β-catenin signaling pathway. Abnormal expression of LRP6 is associated with the malignant phenotype, metastatic potential and poor prognosis of various tumors. In this study, we found that LRP6 was abnormally highly expressed in a variety of tumors and significantly correlated with microsatellite instability, tumor mutation burden, and immune cell infiltration and immune checkpoint expression in a variety of tumors. Moreover, we found that LRP6 was significantly associated with the prognosis of renal clear cell carcinoma. Further we found a significant correlation between LRP6 and the expression of m6A-related genes and ferroptosis-related genes. Finally, we also found a significant correlation between the expression of LRP6 and the sensitivity to common drugs used in kidney clear cell carcinoma treatment. These results suggest that LRP6 is likely to be a potential target for kidney clear cell carcinoma treatment.

摘要

肾细胞癌是最常见且致死率最高的泌尿生殖系统肿瘤。肾透明细胞癌的病因复杂，肿瘤组织的异质性高，因此患者的治疗效果不太理想。探索肾透明细胞癌进展过程中的生物标志物对于改善其诊断和指导治疗至关重要。低密度脂蛋白受体相关蛋白6（LRP6）是Wnt/β-连环蛋白信号通路的共受体，通过激活Wnt/β-连环蛋白信号通路参与细胞生长、炎症和细胞转化。LRP6的异常表达与多种肿瘤的恶性表型、转移潜能及不良预后相关。在本研究中，我们发现LRP6在多种肿瘤中异常高表达，且与多种肿瘤的微卫星不稳定性、肿瘤突变负荷、免疫细胞浸润及免疫检查点表达显著相关。此外，我们发现LRP6与肾透明细胞癌的预后显著相关。进一步地，我们发现LRP6与m6A相关基因及铁死亡相关基因的表达存在显著相关性。最后，我们还发现LRP6的表达与肾透明细胞癌治疗中常用药物的敏感性存在显著相关性。这些结果表明，LRP6很可能是肾透明细胞癌治疗的一个潜在靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33d/10866424/ca25be7a2068/aging-16-205440-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33d/10866424/1449f25d241f/aging-16-205440-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33d/10866424/17c574d28428/aging-16-205440-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33d/10866424/2fa7158373f1/aging-16-205440-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33d/10866424/be3a585bd1f7/aging-16-205440-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33d/10866424/4f6b7da580f6/aging-16-205440-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33d/10866424/99a49ac5ac91/aging-16-205440-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33d/10866424/0799a8eeb610/aging-16-205440-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33d/10866424/ca25be7a2068/aging-16-205440-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33d/10866424/1449f25d241f/aging-16-205440-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33d/10866424/17c574d28428/aging-16-205440-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33d/10866424/2fa7158373f1/aging-16-205440-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33d/10866424/be3a585bd1f7/aging-16-205440-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33d/10866424/4f6b7da580f6/aging-16-205440-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33d/10866424/99a49ac5ac91/aging-16-205440-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33d/10866424/0799a8eeb610/aging-16-205440-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c33d/10866424/ca25be7a2068/aging-16-205440-g008.jpg

相似文献

1
LRP6 is a potential biomarker of kidney clear cell carcinoma related to prognosis and immune infiltration.低密度脂蛋白受体相关蛋白6（LRP6）是一种与肾透明细胞癌预后及免疫浸润相关的潜在生物标志物。
Aging (Albany NY). 2024 Jan 15;16(2):1484-1495. doi: 10.18632/aging.205440.
2
Receptor tyrosine kinase-like orphan receptor 2 (Ror2) expression creates a poised state of Wnt signaling in renal cancer.受体酪氨酸激酶样孤儿受体 2（Ror2）的表达在肾癌中创造了一个 Wnt 信号的平衡状态。
J Biol Chem. 2013 Sep 6;288(36):26301-26310. doi: 10.1074/jbc.M113.466086. Epub 2013 Jul 26.
3
The LRP6 functional mutation rs2302685 contributes to individual susceptibility to alcoholic liver injury related to the Wnt/β-catenin-TCF1-CYP2E1 signaling pathway.LRP6 功能突变 rs2302685 与 Wnt/β-catenin-TCF1-CYP2E1 信号通路相关，导致个体易患酒精性肝损伤。
Arch Toxicol. 2019 Jun;93(6):1679-1695. doi: 10.1007/s00204-019-02447-0. Epub 2019 Apr 11.
4
Upregulation of the Wnt co-receptor LRP6 promotes hepatocarcinogenesis and enhances cell invasion.LRP6 是 Wnt 共受体，其表达上调促进肝癌发生，并增强细胞侵袭。
PLoS One. 2012;7(5):e36565. doi: 10.1371/journal.pone.0036565. Epub 2012 May 3.
5
Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway.尼克罗米胺通过诱导 Wnt 共受体 LRP6 降解和抑制 Wnt/β-连环蛋白通路来抑制癌细胞生长。
PLoS One. 2011;6(12):e29290. doi: 10.1371/journal.pone.0029290. Epub 2011 Dec 16.
6
LRP6 mediates Wnt/β-catenin signaling and regulates adipogenic differentiation in human mesenchymal stem cells.LRP6 介导 Wnt/β-连环蛋白信号通路并调节人骨髓间充质干细胞的成脂分化。
Int J Biochem Cell Biol. 2012 Nov;44(11):1970-82. doi: 10.1016/j.biocel.2012.07.025. Epub 2012 Aug 2.
7
Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer.致癌性KRAS信号通过低密度脂蛋白受体相关蛋白6（LRP6）促进结直肠癌中的Wnt/β-连环蛋白信号通路。
Oncogene. 2015 Sep 17;34(38):4914-27. doi: 10.1038/onc.2014.416. Epub 2014 Dec 15.
8
MiR-30a suppresses clear cell renal cell carcinoma proliferation and metastasis by targeting LRP6.miR-30a 通过靶向 LRP6 抑制肾透明细胞癌细胞的增殖和转移。
Hum Cell. 2021 Mar;34(2):598-606. doi: 10.1007/s13577-020-00472-1. Epub 2021 Jan 5.
9
Silibinin inhibits Wnt/β-catenin signaling by suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cells.水飞蓟宾通过抑制人前列腺和乳腺癌细胞中 Wnt 共受体 LRP6 的表达来抑制 Wnt/β-连环蛋白信号通路。
Cell Signal. 2012 Dec;24(12):2291-6. doi: 10.1016/j.cellsig.2012.07.009. Epub 2012 Jul 20.
10
LRP6 regulates Rab7-mediated autophagy through the Wnt/β-catenin pathway to modulate trophoblast cell migration and invasion.LRP6 通过 Wnt/β-catenin 通路调节 Rab7 介导的自噬，从而调节滋养层细胞的迁移和侵袭。
J Cell Biochem. 2020 Feb;121(2):1599-1609. doi: 10.1002/jcb.29394. Epub 2019 Sep 23.

本文引用的文献

1
Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab.帕博利珠单抗联合阿昔替尼与伊匹单抗联合纳武利尤单抗治疗转移性肾细胞癌患者的真实世界临床结局。
Urol Oncol. 2023 Nov;41(11):459.e1-459.e8. doi: 10.1016/j.urolonc.2023.08.009. Epub 2023 Sep 17.
2
DPP9 Stabilizes NRF2 to Suppress Ferroptosis and Induce Sorafenib Resistance in Clear Cell Renal Cell Carcinoma.DPP9 通过稳定 NRF2 抑制肾透明细胞癌中的铁死亡并诱导索拉非尼耐药。
Cancer Res. 2023 Dec 1;83(23):3940-3955. doi: 10.1158/0008-5472.CAN-22-4001.
3
Prognostic Significance of Grade Discrepancy Between Primary Tumor and Venous Thrombus in Nonmetastatic Clear-cell Renal Cell Carcinoma: Analysis of the REMEMBER Registry and Implications for Adjuvant Therapy.
原发性肿瘤与静脉血栓中分级差异对非转移性透明细胞肾细胞癌的预后意义：REMEMBER 登记处分析及其对辅助治疗的影响。
Eur Urol Oncol. 2024 Feb;7(1):112-121. doi: 10.1016/j.euo.2023.06.006. Epub 2023 Jul 18.
4
Proteogenomics of clear cell renal cell carcinoma response to tyrosine kinase inhibitor.透明细胞肾细胞癌对酪氨酸激酶抑制剂反应的蛋白质基因组学研究
Nat Commun. 2023 Jul 17;14(1):4274. doi: 10.1038/s41467-023-39981-6.
5
Emerging Targets in Clear Cell Renal Cell Carcinoma.透明细胞肾细胞癌的新兴靶点
Cancers (Basel). 2022 Oct 4;14(19):4843. doi: 10.3390/cancers14194843.
6
Fatty acid metabolism reprogramming in ccRCC: mechanisms and potential targets.脂肪酸代谢重编程在 ccRCC 中的作用机制及潜在靶点
Nat Rev Urol. 2023 Jan;20(1):48-60. doi: 10.1038/s41585-022-00654-6. Epub 2022 Oct 3.
7
Ferroptosis in cancer therapy: a novel approach to reversing drug resistance.铁死亡在癌症治疗中的作用：逆转耐药性的新策略
Mol Cancer. 2022 Feb 12;21(1):47. doi: 10.1186/s12943-022-01530-y.
8
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.抗 PD-1 反应和耐药的决定因素在透明细胞肾细胞癌中。
Cancer Cell. 2021 Nov 8;39(11):1497-1518.e11. doi: 10.1016/j.ccell.2021.10.001. Epub 2021 Oct 28.
9
The role of m6A modification in the biological functions and diseases.m6A 修饰在生物学功能和疾病中的作用。
Signal Transduct Target Ther. 2021 Feb 21;6(1):74. doi: 10.1038/s41392-020-00450-x.
10
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.